TG THERAPEUTICS, INC. (TGTX) Operating Margin
- Operating margin · 12 months: Value 17.05%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 17.05% | Operating income / revenue. Period ending 2026-06-30. $136.33M ÷ $799.54M × 100 ≈ 17.05% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 136.33M USD | Operating Income (Loss) |
| Revenue | 799.54M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 140.94M USD | Cost of Goods and Services Sold |
| Research and development | 225.80M USD | Research and Development Expense |
| Selling, general and administration | 296.46M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $136.33M | $799.54M | $140.94M | $225.80M | $296.46M | 17.05% |
| 2026-03-31 | $149.50M | $700.35M | $118.68M | $162.25M | $269.92M | 21.35% |
| 2025-12-31 | $123.32M | $616.29M | $100.71M | $160.22M | $232.03M | 20.01% |
| 2025-09-30 | $102.78M | $531.90M | $77.97M | $142.90M | $208.25M | 19.32% |
| 2025-06-30 | $85.85M | $454.07M | $59.22M | $122.16M | $186.84M | 18.91% |
| 2025-03-31 | $59.82M | $386.39M | $48.59M | $107.93M | $170.05M | 15.48% |
| 2024-12-31 | $41.93M | $329.00M | $38.49M | $94.29M | $154.30M | 12.74% |
| 2024-09-30 | $-505.00K | $264.79M | $30.94M | $87.87M | $146.49M | -0.19% |
| 2024-06-30 | $101.84M | $346.72M | $25.11M | $82.48M | $137.29M | 29.37% |
| 2024-03-31 | $48.35M | $289.33M | $18.71M | $93.04M | $129.22M | 16.71% |
| 2023-12-31 | $20.63M | $233.66M | $14.13M | $76.19M | $122.71M | 8.83% |
| 2023-09-30 | $-18.94M | $189.77M | (m) | $88.38M | $114.06M | -9.98% |
| 2023-06-30 | $-168.69M | $24.05M | (m) | $94.43M | $95.54M | -701.36% |
| 2023-03-31 | $-162.96M | $8.57M | (m) | $93.18M | $77.47M | -1901.06% |
| 2022-12-31 | $-192.84M | $2.79M | (m) | $125.35M | $70.01M | -6924.20% |
| 2022-09-30 | $-233.72M | $5.03M | (m) | $158.36M | $79.92M | -4650.30% |
| 2022-06-30 | $-283.89M | $6.96M | (m) | $189.53M | $100.56M | -4078.28% |
| 2022-03-31 | $-322.44M | $7.91M | (m) | $207.53M | $121.94M | -4075.33% |
| 2021-12-31 | $-344.77M | $6.69M | (m) | $222.58M | $128.09M | -5154.28% |
| 2021-09-30 | $-338.61M | $4.41M | (m) | $202.89M | (m) | -7685.09% |
| 2021-06-30 | $-339.20M | $2.41M | (m) | $201.39M | (m) | -14051.28% |
| 2021-03-31 | $-312.55M | $907.00K | (m) | $192.97M | (m) | -34459.87% |
| 2020-12-31 | $-273.59M | $152.00K | (m) | $165.90M | (m) | -179996.05% |
| 2020-09-30 | $-224.77M | $152.00K | (m) | $153.88M | (m) | -147876.97% |
| 2020-06-30 | $-199.91M | $152.00K | (m) | $161.40M | (m) | -131521.71% |
| 2020-03-31 | $-184.61M | $152.00K | (m) | $157.82M | (m) | -121454.61% |
| 2019-12-31 | $-169.06M | $152.00K | (m) | $154.18M | (m) | -111220.39% |
| 2019-09-30 | $-185.24M | $152.00K | (m) | $175.51M | (m) | -121871.05% |
| 2019-06-30 | $-190.09M | $152.00K | (m) | $150.92M | (m) | -125059.21% |
| 2019-03-31 | $-167.51M | $152.00K | (m) | $156.76M | (m) | -110205.26% |
| 2018-12-31 | $-174.40M | $152.00K | (m) | $159.39M | (m) | -114736.84% |
| 2018-09-30 | $-151.28M | (m) | (m) | $133.11M | (m) | (m) |
| 2018-06-30 | $-148.54M | (m) | (m) | $126.86M | (m) | (m) |
| 2018-03-31 | $-132.62M | (m) | (m) | $114.87M | (m) | (m) |
| 2017-12-31 | $-118.71M | (m) | (m) | $102.53M | (m) | (m) |
| 2017-09-30 | $-111.71M | (m) | (m) | $98.82M | (m) | (m) |
| 2017-06-30 | $-105.05M | (m) | (m) | $93.47M | (m) | (m) |
| 2017-03-31 | $-92.64M | (m) | (m) | $80.30M | (m) | (m) |
| 2016-12-31 | $-78.97M | (m) | (m) | $69.23M | (m) | (m) |
| 2016-09-30 | $-72.58M | (m) | (m) | $62.20M | (m) | (m) |
| 2016-06-30 | $-61.48M | (m) | (m) | $51.98M | (m) | (m) |
| 2016-03-31 | $-62.57M | (m) | (m) | $49.71M | (m) | (m) |
| 2015-12-31 | $-63.18M | (m) | (m) | $47.71M | (m) | (m) |
| 2015-09-30 | $-64.26M | (m) | (m) | $47.59M | (m) | (m) |
| 2015-06-30 | $-67.87M | (m) | (m) | $49.71M | (m) | (m) |
| 2015-03-31 | $-62.72M | (m) | (m) | $45.29M | (m) | (m) |
| 2014-12-31 | $-55.72M | (m) | (m) | $40.09M | (m) | (m) |
| 2014-09-30 | $-44.98M | (m) | (m) | $28.71M | (m) | (m) |
| 2014-06-30 | $-32.18M | (m) | (m) | $18.32M | (m) | (m) |
| 2014-03-31 | $-26.86M | (m) | (m) | $16.50M | (m) | (m) |
| 2013-12-31 | $-22.97M | (m) | (m) | $13.66M | (m) | (m) |
| 2013-09-30 | $-18.68M | (m) | (m) | $10.99M | (m) | (m) |
| 2013-06-30 | $-16.75M | (m) | (m) | $9.24M | (m) | (m) |
| 2013-03-31 | $-13.22M | (m) | (m) | $5.86M | (m) | (m) |
| 2012-12-31 | $-26.90M | (m) | (m) | $21.03M | (m) | (m) |
| 2012-09-30 | $-23.76M | (m) | (m) | $19.96M | (m) | (m) |
| 2012-06-30 | $-21.08M | (m) | (m) | $18.42M | (m) | (m) |
| 2012-03-31 | $-18.27M | (m) | (m) | $17.07M | (m) | (m) |
| 2011-12-31 | $-881.97K | (m) | (m) | $327.28K | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |